CM
PROF

CM Management’s Profound Medical PROF Stock Holding History

CM Management’s Portfolio PROF Stock Details PROF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.13M Buy
175,000
+95,000
+119% +$656K 0.95% 45
2025
Q4 		$630K Buy
+80,000
New +$514K 0.53% 50

Other funds holding PROF

Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
TIM
Timelo Investment Management Aurora, Ontario, Canada $127M AUM 23.73% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
GA
Gagnon Advisors New York $136M AUM 21.55% 1-Year Est. Return
LBA
Letko, Brosseau & Associates Montreal, Quebec, Canada $6.2B AUM 38.92% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
ZCP
Z3 Capital Partners Richmond, Virginia $395M AUM
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

CM Management's PROF Position: Q1 2026 in Review

CM Management increased its Profound Medical (PROF) stake by 119% in Q1 2026, buying an estimated $656K and bringing the position to 175,000 shares worth $1.13M. The position accounts for 0.95% of the portfolio, ranked #45.

CM Management first reported a position in PROF in Q4 2025 and has held it in 2 quarters since. 57 funds tracked by Wall St. Rank hold PROF as of Q1 2026.

  • CM Management held 175,000 shares of Profound Medical worth $1.13M as of Q1 2026.
  • CM Management bought 95,000 Profound Medical shares in Q1 2026, an estimated $656K.
  • Profound Medical made up 0.95% of CM Management's portfolio in Q1 2026, its #45 holding.
  • CM Management first reported a position in Profound Medical in Q4 2025 and has held it in 2 quarters since.
  • 57 funds tracked by Wall St. Rank held Profound Medical as of Q1 2026.

Based on CM Management's 13F filing for Q1 2026, filed 8 May 2026.